View by Tumor Type
Breast Cancer
Home › All Therapies › Truqap

Truqap

capivasertib
AKT Inhibitor FDA Approved 2023 AstraZeneca
Route
Oral
Half-Life
~8 hrs
FDA Approved
2023
Manufacturer
AstraZeneca
Navigation -->
1. Indications and Usage

HR+/HER2- BC with PIK3CA/AKT1/PTEN alterations + fulvestrant.

2. Dosage and Administration

400 mg BID 4on/3off.

3. Dosage Forms and Strengths

Tablets: 200 mg

4. Contraindications

None listed.

5. Warnings and Precautions
  • Hyperglycemia: Monitor.
  • Diarrhea: Manage.
  • Embryo-Fetal Toxicity: Fetal harm.
6. Adverse Reactions
Most Common Adverse Reactions

Diarrhea (72%), Rash (38%), Nausea (34%), Fatigue (28%), Hyperglycemia (22%), Vomiting (21%)

Diarrhea
72%
Rash
38%
Nausea
34%
Fatigue
28%
Hyperglycemia
22%
Vomiting
21%

Consult the complete prescribing information for a comprehensive list of adverse reactions and their frequencies.

7. Drug Interactions

Avoid strong CYP3A4 modulators.

8. Use in Specific Populations
Pregnancy

Consult the full prescribing information for pregnancy-related considerations.

Lactation

Refer to prescribing information for lactation guidance.

Pediatric Use

Pediatric safety and efficacy information is detailed in the full label.

Hepatic/Renal Impairment

Dose modifications for organ impairment are specified in the complete prescribing information.

12. Clinical Pharmacology
Mechanism of Action

Selective AKT1/2/3 inhibitor.

Pharmacokinetics

t1/2: 8h.

14. Clinical Studies

Clinical efficacy and safety data supporting the approval are available in the full prescribing information and from the clinical trials listed below.

Pivotal Clinical Trials
Additional Resources
📋 All Truqap Trials on ClinicalTrials.gov ↗ 📚 PubMed: Truqap Clinical Trials ↗
FDA-Approved Tumor Types

Truqap has FDA-approved indications across the following cancer types covered on CancerDrugEvidence:

Breast Cancer
External Resources
📋 DailyMed Label ↗ 🏛️ FDA Drugs@FDA ↗ 🔬 ClinicalTrials.gov ↗ 📚 PubMed Pivotal Trials ↗
Important Notice: This page is intended as a navigational reference to the FDA-approved prescribing information for Truqap. It does not replace the full prescribing information. Healthcare professionals should consult the complete package insert available at DailyMed before making prescribing decisions. Patient-specific factors should always guide clinical decision-making.

Frequently Asked Questions

What is Truqap (capivasertib) approved for?

Truqap (capivasertib) is an FDA-approved oncology agent. Refer to the full prescribing information for complete indication details.

How is Truqap (capivasertib) administered?

Refer to the full prescribing information for dosing schedules, administration instructions, and dose modifications.

How does Truqap (capivasertib) work?

Selective AKT1/2/3 inhibitor.

What are the most common side effects?

Diarrhea (72%), Rash (38%), Nausea (34%), Fatigue (28%), Hyperglycemia (22%), Vomiting (21%) Diarrhea 72% Rash 38% Nausea 34% Fatigue 28% Hyperglycemia 22% Vomiting 21%

← All Therapies Full Prescribing Information ↗